ElisavetPaplomataMD

Oncology • Madison, WI

Breast Cancer, Gynecologic Cancer

Assistant Professor, Hematology, Medical Oncology

Join to view full profile

Dr. Paplomata is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Paplomata's full profile

Already have an account?

Office
Madison
Madison, WI 53792

Education & Training

Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2011 - 2014
Texas Health Resources (Dallas)Residency, Internal Medicine, 2008 - 2011
Istanbul University FomClass of 2001

Certifications & Licensure

TX State Medical License 2024 - 2026
KY State Medical License 2024 - 2025
OK State Medical License 2024 - 2025
WI State Medical License 2019 - 2025
GA State Medical License 2013 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores Start of enrollment: 2009 Apr 01
Terminated
Phase 2
Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer Start of enrollment: 2009 May 01
Completed
Phase 2
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers Start of enrollment: 2009 Jul 01
Completed
Phase 2
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer Start of enrollment: 2010 Jun 01
Terminated
Phase 2
Phase II Study of Everolimus Beyond Progression Start of enrollment: 2014 Nov 25
Terminated
Phase 2
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer Start of enrollment: 2016 Jan 28
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

707 citations
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi Krishna Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton
The New England Journal of Medicine. 2020-02-13
310 citations
Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER...
Nan Lin, Virginia F. Borges, Carey K. Anders, Rashmi Krishna Murthy, Elisavet Paplomata
Journal of Clinical Oncology. 2020-05-29
111 citations
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB...
G Curigliano, V Mueller, V Borges, E Hamilton, S Hurvitz
Annals of Oncology. 2022-03-01

Journal Articles

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer
Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology

Authored Content

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020

Press Mentions

At the Intersection of Breast and Gynecologic Cancers: Dr. Elisavet PaplomataMay 14th, 2020
mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast CancerMarch 27th, 2015

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Greek, Turkish, French